ABIOMED (NASDAQ: ABMD) has recently received a number of price target changes and ratings updates:

  • 8/10/2017 – ABIOMED was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 8/7/2017 – ABIOMED was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Over the last one month, Abiomed has been trading above the broader Medical Instruments industry. Management expects that robust demand for the Impella product line will continue to drive Abiomed’s top line. The company’s expanding product portfolio will improve penetration into both the prophylactic high-risk PCI and cardiogenic shock patient market. This is evident from the fact that both Impella 2.5 and CP continue to add centers in the U.S. The company also announced the successful launch of the Abiomed Impella Quality Program in fiscal 2017 to improve clinical outcomes. Also, cost-savings efforts remain encouraging. Furthermore, a rising estimate revision trend for the current year indicates a pocket of opportunity for the stock. However, intensifying competition in the niche markets is likely to mar prospects over the long haul.”
  • 8/4/2017 – ABIOMED had its price target raised by analysts at Jefferies Group LLC from $165.00 to $175.00. They now have a “buy” rating on the stock.
  • 7/27/2017 – ABIOMED had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $160.00 price target on the stock, up previously from $145.00.
  • 7/25/2017 – ABIOMED was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/13/2017 – ABIOMED was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $163.00 price target on the stock. According to Zacks, “Over the last one month, Abiomed has been trading above the broader Medical Instruments industry. Management expects that robust demand for the Impella product line will continue to drive Abiomed’s top line. The company’s expanding product portfolio will improve penetration into both the prophylactic high-risk PCI and cardiogenic shock patient market. This is evident from the fact that both Impella 2.5 and CP continue to add centers in the U.S. The company also announced the successful launch of the Abiomed Impella Quality Program in fiscal 2017 to improve clinical outcomes. Also, cost-savings efforts remain encouraging. Furthermore, a rising estimate revision trend for the current year indicates a pocket of opportunity for the stock. However, intensifying competition in the niche markets is likely to mar prospects over the long haul.”
  • 7/10/2017 – ABIOMED had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $140.00 price target on the stock, up previously from $135.00.
  • 7/5/2017 – ABIOMED was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Abiomed posted a promising fourth quarter of fiscal 2017, with revenues beating the Zacks Consensus Estimate and earnings meeting the mark. We believe that robust demand for the Impella product line will continue to drive Abiomed’s top line. The company’s expanding product portfolio will improve penetration into both the prophylactic high-risk PCI and cardiogenic shock patient market. This is evident from the fact that both Impella 2.5 and CP continue to add centers in the U.S. The company also announced the successful launch of the Abiomed Impella Quality Program in the fourth quarter to improve clinical outcomes. However, intensifying competition in the niche markets is likely to mar prospects over the long haul. Although Abiomed’s significant international presence helps broaden its customer base, fluctuations in currency exchange rates may impact international sales.”
  • 7/4/2017 – ABIOMED was given a new $145.00 price target on by analysts at Piper Jaffray Companies.
  • 6/28/2017 – ABIOMED was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.

Shares of ABIOMED, Inc. (ABMD) traded down 3.75% on Thursday, reaching $150.01. The company had a trading volume of 382,560 shares. ABIOMED, Inc. has a 1-year low of $95.14 and a 1-year high of $157.41. The company’s 50 day moving average price is $145.21 and its 200-day moving average price is $130.31. The stock has a market capitalization of $6.58 billion, a P/E ratio of 87.73 and a beta of 0.20.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.03. ABIOMED had a return on equity of 13.03% and a net margin of 16.13%. The business had revenue of $132.47 million for the quarter, compared to analyst estimates of $130.83 million. During the same quarter in the prior year, the company earned $0.29 earnings per share. The company’s revenue was up 28.6% on a year-over-year basis. Equities analysts predict that ABIOMED, Inc. will post $2.24 EPS for the current year.

In other news, VP Michael G. Howley sold 18,279 shares of the company’s stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $133.56, for a total transaction of $2,441,343.24. Following the sale, the vice president now owns 62,105 shares of the company’s stock, valued at $8,294,743.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO David M. Weber sold 16,500 shares of the company’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $147.63, for a total value of $2,435,895.00. Following the sale, the chief operating officer now directly owns 125,122 shares in the company, valued at approximately $18,471,760.86. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by corporate insiders.

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Receive News & Ratings for ABIOMED Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc and related companies with MarketBeat.com's FREE daily email newsletter.